Skip to main content
Basilea Pharmaceutica AG logo

Basilea Pharmaceutica AG — Investor Relations & Filings

Ticker · BSLN ISIN · CH0011432447 LEI · 391200TTZP8EIPSJ5J20 SW Manufacturing
Open in API
Filings indexed 57 across all filing types
Latest filing 2024-08-27 Legal Proceedings Report
Country CH Switzerland
Listing SW BSLN

About Basilea Pharmaceutica AG

https://www.basilea.com/

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company that develops and commercializes innovative pharmaceutical products. The company focuses on meeting the medical needs of patients with severe and life-threatening conditions, particularly bacterial and fungal infections. Its core activities revolve around its key anti-infective products, Cresemba and Zevtera, with a strategy to establish them as global brands. Basilea has a proven track record of advancing drugs from research and development through to market commercialization, aiming to become a leading company in the anti-infectives field.

Recent filings

Filing Released Lang Actions
Entscheidung der Europäischen Kommission zur Zulassung von Antipilzmittel Cresemba® (Isavuconazol) bei Kindern und Verlängerung der Marktexklusivität löst CHF 10 Mio. Meilensteinzahlung an Basilea aus
Legal Proceedings Report Classification · 99% confidence The document is titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and is dated August 27, 2024. It announces a specific corporate event: the European Commission's approval extension for the drug Cresemba in pediatric treatment, which triggered a CHF 10 million milestone payment from Pfizer. This type of immediate, material, non-scheduled corporate news release, especially one concerning regulatory decisions and financial milestones, is typically classified as a general regulatory announcement or press release that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a formal, immediate disclosure required by market rules (Ad hoc), and it doesn't fit the definitions for Dividends (DIV), Earnings Release (ER), or Capital Changes (CAP), the most appropriate general category for significant, unscheduled regulatory news that isn't a specific report is Regulatory Filings (RNS). The document length (6630 chars) is substantial enough to be the primary announcement itself, not just a pointer to an attachment, although it does link to a PDF press release. Given the content is a direct announcement of a regulatory/financial event, RNS is the best fit among the provided options for a non-standard, mandatory disclosure.
2024-08-27 German
Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance
Earnings Release Classification · 100% confidence The document is explicitly titled 'Ad hoc announcement pursuant to Art. 53 LR' and details the financial results for the 'first half-year ended June 30, 2024'. It provides a summary of key financial figures (revenue, operating result, net profit) and updates the full-year financial guidance. This content structure—a summary of period results and updated guidance—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it contains a detailed financial summary table and management commentary on the period's performance, it goes beyond a simple 'key highlights only' release, leaning towards a comprehensive interim report. However, the document is an 'Ad hoc announcement' and mentions that the 'unaudited, condensed consolidated interim financial statements... can be found on the company’s website'. This suggests the document itself is the announcement summarizing the period's performance, which aligns best with the definition of an Earnings Release (ER) or, given the depth of financial detail, an Interim Report (IR). Given the explicit reporting of H1 2024 results, IR is the most appropriate classification for a comprehensive period report, even if presented as an ad hoc announcement. H1 2024
2024-08-13 English
Basilea meldet starke Halbjahresergebnisse 2024 und erhöht signifikant den Ausblick für Umsatz und Gewinn für das Gesamtjahr
Earnings Release Classification · 100% confidence The document is explicitly titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and details the financial results for the first half of the fiscal year 2024 (H1 2024), including revenue, operating income, profit, and updated full-year guidance. This content structure—a summary of period results, management commentary, key financial tables, and updated outlook—is characteristic of an Earnings Release (ER). Although it contains comprehensive financial data, it is presented as an immediate announcement following the end of the reporting period, rather than a full, audited Annual Report (10-K) or a comprehensive Interim Report (IR) which typically follows a more structured regulatory filing format. Since it is the initial release of period results, ER is the most appropriate classification. The document also announces a conference call to discuss these results, further supporting the ER classification. H1 2024
2024-08-13 German
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
Regulatory Filings Classification · 100% confidence The document is titled "Ad hoc announcement pursuant to Art. 53 LR" and details the US FDA approval of the drug ZEVTERA®. It contains significant business news (regulatory approval, commercial outlook, financial commentary) released by a listed company (Basilea Pharmaceutica Ltd). This type of material, which is a significant, non-periodic corporate event announcement, is typically classified as a general Regulatory Filing (RNS) if it doesn't fit a more specific category like Earnings Release (ER) or Capital Update (CAP). Since this is a major regulatory milestone announcement (FDA approval) and not a standard financial report (10-K, IR, ER), nor a management/board change, the most appropriate general category for significant, non-standard corporate news that must be disclosed is Regulatory Filings (RNS). It is not a proxy statement (DEF 14A/PSI), nor a management/board change (MANG). It is an announcement of a major event, not a report itself, so RPA is less fitting than RNS for this type of regulatory news release.
2024-04-04 English
Basilea gibt Erhalt der US-FDA-Zulassung für Antibiotikum ZEVTERA® (Ceftobiprol-Medocaril) für drei Indikationen bekannt
Regulatory Filings Classification · 100% confidence The document is titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and is dated April 4, 2024. It announces a significant corporate event: the US FDA approval of the antibiotic ZEVTERA for several indications. This type of announcement, detailing a major regulatory or corporate development, is typically classified as a general regulatory filing or an announcement. Since it is a direct announcement of a key event (FDA approval) and not a recurring financial report (like 10-K, IR, or ER), and it doesn't fit specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate classification is a general Regulatory Filing (RNS), which serves as a broad category for important, non-standard announcements, especially those mandated by stock exchange rules (KR/SIX). The document length is substantial (over 12k characters), so it is the primary announcement itself, not just a pointer to another document (which would be RPA).
2024-04-04 German
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and provides a summary of financial results for the financial year ended December 31, 2023, including key metrics like revenue, operating profit, and net profit, along with forward-looking guidance for FY 2024. This structure—a brief announcement highlighting key figures and referencing the full financial statements elsewhere—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the detailed Interim Report (IR), but rather the initial public announcement of the period's results. The document also mentions a conference call to discuss these results, further supporting the ER classification. FY 2023
2024-02-13 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.